Click-based GalNac-RNA Delivery Service
Overview
The clinical success of RNA therapeutics is fundamentally tethered to the efficiency of tissue-specific delivery. While lipid nanoparticles (LNPs) have revolutionized the field, the emergence of ligand-conjugated oligonucleotides offers a "lock-and-key" precision that maximizes potency while minimizing systemic toxicity. CD BioGlyco specializes in click chemistry-based GalNAc-RNA delivery services, leveraging the highly efficient asialoglycoprotein receptor (ASGPR) pathway. By utilizing bioorthogonal click chemistry, we achieve site-specific, high-yield conjugation of trivalent N-acetylgalactosamine (GalNAc) clusters to your therapeutic RNA. This platform is specifically designed to overcome the pharmacokinetic hurdles of "naked" oligonucleotides, ensuring robust internalization into hepatocytes for durable gene silencing or modulation.
Core Technologies
Our platform integrates the Nobel Prize-winning principles of click chemistry with advanced carbohydrate engineering to deliver a superior targeting vehicle:
- Strain-Promoted Alkyne-Azide Cycloaddition (SPAAC)
We utilize copper-free click chemistry with dibenzocyclooctyne (DBCO) moieties. This biorthogonal reaction occurs under mild, physiological conditions without the need for toxic metal catalysts, preserving the integrity of sensitive RNA species.
- Trivalent GalNAc Architecture
Our proprietary trivalent ligands are engineered to mirror the natural stoichiometry of the trimeric ASGPR. This multivalent interaction significantly enhances binding avidity (nanomolar affinity) compared to monovalent designs, facilitating rapid endocytosis.
- Advanced ESC (Enhanced Stability Chemistry)
We combine click conjugation with strategic 2'-O-methyl (2'-OMe) and 2'-deoxy-2'-fluoro (2'-F) modifications. This dual approach protects the conjugate from exonuclease degradation and ensures a long-lasting intracellular reservoir.
- Modular Linker Technology
Our service offers a range of customizable linkers, including PEG-based spacers for solubility and bioreversible (cleavable) bonds that optimize the release of the RNA payload within the endosomal compartment.
The Smarter Click for RNA.
The click chemistry-based GalNAc-RNA delivery service provides a comprehensive solution for researchers transitioning from discovery to pre-clinical development. Our scope encompasses the custom synthesis of a wide array of oligonucleotide modalities, including siRNA, antisense oligonucleotides (ASOs), microRNAs (miRNAs), and even larger aptamers. We offer unprecedented flexibility in conjugation sites, allowing for 5'-end, 3'-end, or multiple internal GalNAc attachments to optimize the therapeutic index for each specific sequence.
Our service is built on a modular platform that supports various scale requirements, from milligram quantities for initial screening to multigram scales for toxicology and NHP studies. Beyond simple conjugation, our scope includes the implementation of enhanced stability chemistry (ESC) and Advanced ESC designs, which are critical for achieving the "months-long" duration of effect observed in modern clinical candidates. We also provide specialized linker design services, offering PEGylated or alkyl spacers to fine-tune the hydrophobicity and bioavailability of the final conjugate. With us, you gain access to a fully integrated pipeline that handles everything from nucleotide synthesis and click chemistry to advanced LC-MS characterization and impurity profiling.
Workflow
Sequence Design & Modification
We conduct a comprehensive analysis of your target RNA (siRNA, ASO, or miRNA) to determine the optimal sites for functionalization, ensuring minimal impact on its biological activity and stability. The synthesis is then performed using solid-phase techniques, precisely incorporating azide groups at predetermined positions, such as the 5' or 3' terminus, or at internal sites—via modified phosphoramidite chemistry. This site-specific modification is critical for enabling subsequent bioorthogonal conjugation while preserving the structural integrity of the RNA molecule.
Click Reaction Implementation
The azide-functionalized RNA undergoes a strain-promoted azide-alkyne cycloaddition (SPAAC) reaction with our custom-synthesized, trivalent GalNAc-DBCO cluster. This copper-free click chemistry approach is conducted under controlled, mild conditions to maximize yield and maintain RNA integrity. We employ real-time monitoring with analytical techniques such as UV spectroscopy or HPLC to track the reaction progress, ensuring quantitative conversion of the RNA and achieving precise stoichiometric control over the final conjugate.
High-Resolution Purification
Following conjugation, the crude product is subjected to a stringent, multi-step purification process. We primarily utilize preparative-scale reverse-phase HPLC (RP-HPLC) or ion-exchange chromatography (IEX), selected based on the physicochemical properties of the specific conjugate. This step effectively separates and removes unreacted ligands, excess reagents, and any trace impurities, consistently yielding conjugates with pharmaceutical-grade purity levels exceeding 98%.
Physicochemical Characterization
Every batch of the final conjugate undergoes a rigorous battery of quality control tests. This includes liquid chromatography-mass spectrometry (LC-MS) for exact mass verification and confirmation of identity, as well as analytical size-exclusion chromatography (SEC) to assess monodispersity, detect any potential aggregates, and ensure the product meets predefined specifications for homogeneity and stability.
In Vitro Potency Validation (Optional)
As an optional service, we can perform targeted in vitro assays to functionally validate the conjugate. These studies typically include surface plasmon resonance (SPR)-based ASGPR-binding assays to quantify targeting ligand affinity, and cell-based uptake studies using relevant hepatocyte models to demonstrate targeted delivery efficiency. This provides critical data on the biological performance of the final product before shipment.
Publication Data
Journal: Molecules
DOI: 10.3390/molecules28207184
IF: 4.6
Published: 2023
Results: This research article presents the development of a novel dithiomaleimide (DTM)-based tetra-antennary GalNAc conjugate designed to enable both efficient siRNA delivery and intrinsic traceability without incorporating external fluorophores. The authors successfully constructed this "two-birds-with-one-stone" system using a series of efficient click-type reactions, including amidations, thiol-dibromomaleimide addition, and CuAAC. The resulting conjugate demonstrated comparable siRNA delivery efficiency to the standard GalNAc-L96 when targeting mouse transthyretin (mTTR), as validated through cellular uptake studies and gene silencing assays in primary mouse hepatocytes. Crucially, the incorporated DTM moieties exhibited strong intrinsic fluorescence, providing a built-in tracking capability that eliminates the need for additional dye molecules, thereby reducing potential side effects and synthesis costs. The study confirms that this innovative approach maintains effective delivery performance while offering enhanced traceability, presenting a promising strategy for advancing RNAi therapeutics by combining delivery functionality and monitoring capabilities within a single molecular entity.
Applications
Chronic Hepatitis B (HBV)
We enable the targeted delivery of antiviral RNA molecules to hepatocytes, where they can silence viral transcripts and potentially lead to functional cure by reducing HBsAg levels effectively.
Transthyretin (ATTR) Amyloidosis
Our click-conjugated siRNAs can precisely target the liver to inhibit the production of TTR protein, addressing the root cause of both hereditary and wild-type amyloid polyneuropathy and cardiomyopathy.
Primary Hyperoxaluria
By delivering siRNAs that silence hydroxyacid oxidase 1 (HAO1), our platform helps reduce hepatic oxalate production, preventing kidney stones and systemic oxalosis in patients with genetic enzyme deficiencies.
Acute Hepatic Porphyrias
We provide the delivery tools to target ALAS1 mRNA in hepatocytes, effectively managing the overproduction of neurotoxic intermediates and preventing the debilitating attacks associated with this rare metabolic disease.
Advantages
Bioorthogonal Precision
Our click chemistry approach ensures that the conjugation reaction only occurs at the designated azide/alkyne sites. This site-specificity eliminates the "messy" mixture of products often found with traditional NHS-ester or maleimide chemistries.
Copper-Free Safety
By utilizing SPAAC (strain-promoted) technology, we avoid the use of copper catalysts. This is critical for biological applications, as it prevents oxidative damage to the RNA and eliminates potential metal toxicity in downstream in vivo studies.
Rapid Internalization Kinetics
The high-affinity trivalent GalNAc ligands we use are rapidly recognized by ASGPR. This leads to the internalization of over a million RNA molecules every 15 minutes per cell, far exceeding the threshold required for therapeutic effect.
Superior Stability in Acidic Media
Our conjugates are engineered to remain stable during endosomal trafficking. Maintaining conjugate integrity within acidic intracellular compartments is the key driver of long-term pharmacological activity.
Frequently Asked Questions
Customer Review
CD BioGlyco's click chemistry platform is a game-changer. The purity of the GalNAc-siRNA conjugates we received was exceptional, and the in vivo potency in our NASH model exceeded all previous benchmarks.
— By Dr. J.H., Director of RNA Discovery
We struggled with copper toxicity using other providers. Switching to CD BioGlyco's SPAAC-based service eliminated our cell viability issues and allowed us to focus on the biology of our target.
— By Manager, Metabolic Research Unit
The team at CD BioGlyco provided incredible support in designing the right linker for our ASO project. Their 5'-trivalent GalNAc conjugates showed a 5-fold improvement in liver uptake.
— By Dr. S.L., Senior Principal Scientist
Associated Services
High-purity, custom siRNA synthesis with a wide range of chemical modifications for maximum stability.
Specialized synthesis of microRNA mimics and inhibitors tailored for gene regulation studies.
Advanced antisense oligonucleotide production featuring phosphorothioate and 2'-MOE modifications.
CD BioGlyco is your premier partner for precision RNA delivery. Our click chemistry-based GalNAc-RNA platform represents the pinnacle of site-specific hepatocyte targeting, offering a robust, scalable, and highly potent solution for your therapeutic needs. From initial design to large-scale synthesis, we provide the expertise and quality control necessary to drive your liver-directed programs forward. Contact us!
Reference
- Kong, S.; et al. Two birds with one stone: a novel dithiomaleimide-based GalNAc-siRNA conjugate enabling good siRNA delivery and traceability. Molecules. 2023, 28(20): 7184. (Open Access)
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform